explore -WSS

explore

author：Wikipedia 2025-09-03 03:25:21 - browse：6

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： 'The Exorcist' director William Friedkin dead at 87

WSS

As a primary care physician, here's how I hope to partner with AI

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

Biogen joins immunology wave with $1.15 billion acquisition of HI

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Addressing health care workers' trauma can help fight burnout

In Memoriam: Notable people who died in 2023

Eyeing GLP

Guidelines to prevent youth baseball injuries need more muscle

Biden will tout long

State Dept. review finds Biden bears some blame for Afghanistan failures

Biogen joins immunology wave with $1.15 billion acquisition of HI

Supreme Court strikes down use of affirmative action

At least 12 people were injured in a blast at a port in northwest Turkey

focus

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Making the case for fair compensation in clinical trials

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

Illinois to ban advertising for guns allegedly marketed to kids and militants

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

focus

entertainment

hotspot

focus